Neurofibromatoses Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Neurofibromatoses Treatment Landscape. Click here to read more @ Neurofibromatoses Pipeline Outlook
Key Takeaways from the Neurofibromatoses Pipeline Report
In June 2025, Healx Limited announced a phase 2 study in 20 participants. The study will assess the tolerability and efficacy of HLX-1502 in participants with NF1 16 years of age or older with progressive and/or symptomatic PN.
In June 2025, Novartis Pharmaceuticals conducted a study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
DelveInsight's Neurofibromatoses pipeline report depicts a robust space with 10+ active players working to develop 12+ pipeline therapies for Neurofibromatoses treatment.
The leading Neurofibromatoses Companies such as Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
Promising Neurofibromatoses Pipeline Therapies such as trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others.
Discover groundbreaking developments in Neurofibromatoses Therapies! Gain in-depth knowledge of key Neurofibromatoses emerging drugs, and market opportunities @ Neurofibromatoses Clinical Trials Assessment
Neurofibromatoses Emerging Drugs Profile
FCN-159: Shanghai Fosun Pharmaceutical
FCN-159 is a novel, proprietary and highly potent inhibitor of mitogen-activated protein kinase kinase enzymes (MEK). It is being developed by Fochon as a monotherapy and in combination to treat solid tumors. MEK is a key member in the RAS/RAF/MEK/ERK pathway, which regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis. Dysregulation of this pathway frequently occurs in many types of cancer, in particular through mutations in BRAF, KRAS and NRAS. Currently, the drug is in Phase III stage of its development for the treatment of Neurofibromatoses.
HLX-1502: Healx Limited
HLX-1502 is an investigational, orally administered small molecule drug developed by Healx for treating Neurofibromatosis Type 1 (NF1), a rare genetic disorder marked by tumor growth along nerves. HLX-1502 was discovered using Healx's proprietary AI platform, which accelerates the identification of potential drug candidates. The therapy has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the U.S. Food and Drug Administration, underscoring its potential significance for the NF1 community. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Neurofibromatosis Type 1.
PAS-004: Pasithea Therapeutics Corp.
PAS-004 is a small molecule allosteric inhibitor of MEK 1/2, which are dual-specificity protein kinases, in the MAPK signaling pathway. The MAPK pathway has been implicated in a variety of diseases, as it functions to drive cell proliferation, differentiation, survival and a variety of other cellular functions that, when abnormally activated, are critical for the formation and progression of tumors, fibrosis and other diseases. MEK inhibitors block phosphorylation (activation) of extracellular signal-regulated kinases (ERK). Currently, the drug is in the Phase I stage of its development for the treatment of Neurofibromatosis Type 1.
The Neurofibromatoses Pipeline Report Provides Insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatoses with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatoses Treatment.
Neurofibromatoses Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neurofibromatoses Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatoses market
Stay informed about the Neurofibromatoses pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Neurofibromatoses Unmet Needs
Neurofibromatoses Companies
Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
Neurofibromatoses Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Neurofibromatoses Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Transform your understanding of the Neurofibromatoses Pipeline! See the latest progress in drug development and clinical research @ Neurofibromatoses Market Drivers and Barriers, and Future Perspectives
Scope of the Neurofibromatoses Pipeline Report
Coverage- Global
Neurofibromatoses Companies- Shanghai Fosun Pharmaceutical, Healx Limited, Pasithea Therapeutics Corp., NFlection Therapeutics Inc., Infixion Bioscience and others.
Neurofibromatoses Pipeline Therapies- Trametinib, dabrafenib, bevacizumab, everolimus, Siltuximab, and others.
Neurofibromatoses Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Neurofibromatoses Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Research-Access the Full Neurofibromatoses Pipeline Analysis Today! @ Neurofibromatoses Drugs and Companies
Table of Contents
Introduction
Executive Summary
Neurofibromatoses: Overview
Pipeline Therapeutics
Therapeutic Assessment
Neurofibromatoses– DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
FCN-159: Shanghai Fosun Pharmaceutical
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
HLX-1502: Healx Limited
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
PAS-004: Pasithea Therapeutics Corp.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Neurofibromatoses Key Companies
Neurofibromatoses Key Products
Neurofibromatoses- Unmet Needs
Neurofibromatoses- Market Drivers and Barriers
Neurofibromatoses- Future Perspectives and Conclusion
Neurofibromatoses Analyst Views
Neurofibromatoses Key Companies
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
14 minutes ago
- Globe and Mail
Will AbbVie's Acquisition Spree Aid Pipeline Growth?
AbbVie ABBV has been actively ramping up its deal-making efforts lately, thereby strengthening its pipeline. While immunology remains its core area, the company is also signing some early-stage deals across various other therapeutic areas, including oncology and neuroscience. Earlier this week, AbbVie signed a definitive agreement to acquire privately held biotech Capstan Therapeutics for a total deal value of nearly $2.1 billion. The transaction, expected to be completed in the third quarter, will add Capstan's lead asset, CPTX2309 — a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy — to its immunology pipeline. The acquisition will also add Capstan's proprietary tLNP platform technology, CellSeeker, which helps deliver RNA, like mRNA, to engineer specific cell types inside the body. Since the beginning of last year, the company has signed over 20 early-stage deals, including promising technologies and innovative mechanisms that can elevate the standard of care across various therapeutic areas. Earlier this year, AbbVie acquired rights to develop a long-acting amylin analog for the treatment of obesity from Denmark's Gubra, marking its foray into the obesity space. It also plans to invest further in obesity. Among some recent larger deals, AbbVie acquired ImmunoGen, which added the ovarian cancer drug Elahere and neuroscience drugmaker Cerevel Therapeutics last year. These acquisitions have not only broadened AbbVie's therapeutic footprint but also diversified its pipeline across multiple modalities. The augmented pipeline now includes next-generation immunology candidates, bispecifics, antibody-drug conjugates and innovative therapies for neuropsychiatric and neurodegenerative disorders. We believe ABBV will continue pursuing such deals to further grow its pipeline. Focus on M&A in 2025 While broader macroeconomic concerns, including Trump-era tariffs and leadership shifts at the FDA, have weighed on deal-making this year, Big Pharma continues to pursue strategic assets in key growth areas. Last month, Eli Lilly LLY announced its intent to acquire cardiology-focused Verve Therapeutics in a deal valued at up to $1.3 billion. This transaction, which is also expected to close in the third quarter, will mark LLY's third targeted M&A deal this year. Earlier in January, it signed a $2.5 billion deal for Scorpion Therapeutics' experimental oncology drug. In May, Lilly agreed to acquire SiteOne Therapeutics for $1 billion to strengthen its neuroscience pipeline. Such deals suggest that LLY's M&A strategy is selective, focusing on long-term strength across therapeutic areas beyond its dominant presence in obesity. In June, Sanofi SNY announced a $9.5 billion acquisition of Blueprint Medicines to strengthen its immunology pipeline and reduce reliance on the blockbuster drug Dupixent. Through this transaction, SNY intends to add Ayvakit — an inhibitor of KIT and PDGFRA proteins with growing commercial traction — and several early-stage pipeline assets focused on systemic mastocytosis (SM). Recently, Sanofi completed the acquisition of an investigational bispecific antibody targeting autoimmune diseases from California-based Dren Bio and also agreed to acquire neurology-focused Vigil Neuroscience in a deal valued at around $470 million. ABBV's Price Performance, Valuation and Estimates Shares of AbbVie have outperformed the industry year to date, as seen in the chart below. From a valuation standpoint, AbbVie is not very cheap. Based on the price/earnings (P/E) ratio, the company's shares currently trade at 14.42 times forward earnings, slightly lower than its industry's average of 14.86. The stock is cheaper than some other large drugmakers, such as Eli Lilly and Novo Nordisk, but priced much higher than most other large drugmakers. The stock is also trading above its five-year mean of 12.46. The Zacks Consensus Estimate for 2025 EPS has risen from $12.26 to $12.28, while that for 2026 has remained consistent at $14.06 over the past 60 days. AbbVie currently has a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report This article originally published on Zacks Investment Research (
National Post
20 minutes ago
- National Post
Innovia Medical Advances Strategic Vision with Acquisitions of Grace Medical and Hurricane Medical
Article content ST. PAUL, Minn. — Innovia Medical, a global medical device company focused on specialty surgical products, announced today the acquisitions of two well-respected specialty medical device companies: Grace Medical, a global leader in Ear, Nose, and Throat (ENT) solutions, and Hurricane Medical, a trusted provider of Ophthalmic surgical products. Article content These acquisitions mark a pivotal milestone in Innovia Medical's continued growth, reinforcing its commitment to building a globally integrated platform of specialty surgical solutions. By uniting distinct areas of expertise and synergistic product portfolios, Innovia Medical is expanding its clinical reach and strengthening its ability to support healthcare providers and patients worldwide. Article content Article content 'Grace Medical and Hurricane Medical have each built strong reputations within ENT and Ophthalmology, and we are proud to bring their expertise and talent into the Innovia Medical family,' said Terry Meredith, CEO of Innovia Medical. 'Grace Medical brings a leading portfolio of highly specialized ENT products that address complex surgical needs, while Hurricane Medical adds a complementary range of Ophthalmic solutions, backed by strong manufacturing capabilities and a deep commitment to customer service. Together, these additions strengthen our ability to deliver comprehensive, high-quality solutions that empower clinicians, improve patient care, and advance our vision for specialty surgical innovation.' Article content Grace Medical, headquartered in Memphis, TN, brings a strong portfolio of advanced ENT technologies and a legacy of clinical leadership. 'We look forward to expanding our ENT presence with Innovia Medical and continuing to service ENT customers around the world,' said Murray Beard, CEO of Grace Medical. Michael Crook, President, Chief Operating Officer of Grace Medical, will lead the strategic direction of the ENT division at Innovia Medical. Reflecting on the partnership, he shared: 'Joining forces with Innovia Medical brings together two highly complementary organizations – creating a world-class ENT platform with the scale, expertise, and product depth needed to better serve specialists and advance patient care.' Article content Hurricane Medical, based in Bradenton, FL, is a respected provider of high-quality Ophthalmic surgical solutions. 'We see a tremendous opportunity to grow Hurricane Medical's product coverage through Innovia Medical's commercial reach and global infrastructure,' said Dell Bauslaugh, President of Hurricane Medical. 'We are excited for what this means for our customers and our team.' Article content Customers and partners can expect continuity in operations, with the same sales and service contacts remaining in place. The integration of these organizations is expected to result in enhanced capabilities, increased resources, broader product portfolios, and a shared commitment to delivering outstanding outcomes for patients and clinicians alike. Article content Innovia Medical and its long-term growth strategy are backed by private investment firm Inverness Graham Investments. Article content About Innovia Medical Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
USANA Executive Chairman Kevin Guest Invites All to Discover Freedom in July
SALT LAKE CITY , /CNW/ -- With freedom as a universal desire being celebrated this month, Kevin Guest , Executive Chairman of USANA Health Sciences (NYSE: USNA), is inspiring individuals and families to celebrate freedom on a personal level for self-care. Research reveals countless global celebrations honoring freedom—from America's Independence Day on July 4 to the unifying spirit of Canada Day on July 1 and numerous others around the world. "Freedom is more than a national observance; it's deeply personal, complex and transformational," said Guest, author of All the Right Reasons: 12 Timeless Principles for Living a Life in Harmony. "Even if freedom may feel out of reach, I invite everyone to take control of their own personal independence and live a life in harmony." To honor freedom in one's life, Guest lists five ways to break free and celebrate the possibilities. Release Limiting Beliefs:"Are you stuck in rigid narratives about what you can or cannot do? Rewrite them," he said. "Freedom flourishes when your belief system aligns with your true potential." Overcome Self-Doubt:"I've learned there is power in silencing the inner critic," Guest said. "To do so, recognize your achievements, no matter how small, and lean into your strengths. Confidence isn't a luxury; it's a necessity." Leave Toxic Relationships Behind:"Whether it's a friendship, partnership or professional connection, anything that drains your energy and stifles your growth needs to be booted. You deserve better," said Guest, who speaks to tens of thousands of associates around the world each year. Defeat Loneliness: Build bridges, not walls. "Surround yourself with people who celebrate your wins and uplift you when life gets you down. A strong network of supporters brings a solid sense of freedom," he said. Say Goodbye to Burnout and People-Pleasing:"Stop setting yourself on fire to keep others warm," said Guest. "It's vital to set boundaries, rest, and celebrate the freedom to prioritize yourself." In one example of negative self-talk, Guest was preparing to perform with Collin Raye's band at the Grand Ole Opry for the first time when his negative self-talk nearly immobilized him. "Standing backstage waiting for our turn to go on, I became increasingly anxious as I convinced myself these negative thoughts were true," Guest wrote in his bestseller. "My hands started shaking, and my mouth went dry. How was I supposed to play and sing? I couldn't remember the notes to the first song, let alone the others that followed. My stomach hurt and my confidence plummeted. All I could think was, 'You're going to screw this up!'" To his relief, he had a successful Grand Ole Opry performance and concluded, "Most of what we worry about never happens or is beyond our control." Simply put, worry hampers creativity, induces anxiety and destroys peace. "I have consistently found my grandfather's words to be true: if you are prepared, good things will happen," Guest said. These five actions above not only reflect personal empowerment but also embody the harmony Guest speaks of in his book. Freedom isn't granted; it's created. It's not something to wait for; it's something to own. "Global celebrations of freedom may vary, but the essence is the same," he said. "Freedom inspires joy, cultivates confidence and transforms lives. Begin today and champion your own independence." More inspiring examples of amplifying self-care are shared throughout All the Right Reasons, where all proceeds go to feeding hungry children. Each book purchase provides 40 meals. For more information, visit USANA Health Sciences, a global leader in health and wellness products, has long recognized the importance of social wellness in building a successful business. From its founding in 1992, USANA has focused on clear and concise communication to build trust with its customers and distributors in 25 countries. For more information about USANA Health Sciences and its dedication to promoting health, wellness, and entrepreneurial success, visit
